16 Raskob GE, Hirsh J. Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery. Chest, 2003, 124( 6 Suppl ): 379 - 385.

17 Prandoni P, Bruchi O, Sabbion P, et al. Prolonged thromboprophylaxis with oral anticoagulants 25.Dahl OE, Bergqvist D.Current controversies in deep vein thrombosis prophylaxis after orthopaedic surgery. Curr Opin Pulm Med, 2002, 8: 394 - 397.

18 Agnelli G, Taliani MR, Verso M. Building effective prophylaxis of deep vein thrombosis in the outpatient setting. Blood Coagul Fibrinolysis, 1999,10 suppl 2: 29 - 35.

19 Dahl OE.Continuing out-of-hospital prophylaxis following major orthopaedic surgery: what now? Haemostasis, 2000, 30 suppl 2: 101 - 105.

20 Comp PC, Spiro TE, Friedman RJ, et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group.J Bone Joint Surg (Am), 2001, 83: 336 - 345.

21 Agnelli G, Mancini GB, Biagini D. The rationale for long-term prophylaxis of venous thromboembolism.Orthopedics, 2000, 23(6 Suppl ): 643 - 646.

22 Committee for Proprietary Medicinal Products：Points to consider on clinical investigation of medicinal products for prophylaxis of intra- and postoperative venous thromboembolic risk. London. 2000. CPMP/EWP， 707 - 708.

23 Dahl OE, Bergqvist D.Current controversies in deep vein thrombosis prophylaxis after orthopaedic surgery. Curr Opin Pulm Med, 2002, 8: 394 - 397.

24 Lie SA, Engesaeter LB, Havelin LI, et al. Early postoperative mortality after 67,548 total hip replacements: causes of death and thromboprophylaxis in 68 hospitals in Norway from 1987 to 1999. Acta Orthop Scand, 2002, 73: 392 - 399.

25 Lie SA, Engesaeter LB, Havelin LI, et al. Mortality after total hip replacement: 0-10-year follow-up of 39,543 patients in the Norwegian Arthroplasty Register.Acta Orthop Scand, 2000, 71: 19 - 27.

26 Ollendorf DA, Vera-Llonch M, Oster G. Cost of venous thromboembolism following major orthopedic surgery in hospitalized patients. Am J Health Syst Pharm, 2002 59:1750 - 1754.

27 Bergqvist D, Jonsson B. Cost-effectiveness of prolonged out-of-hospital prophylaxis with low-molecular-weight heparin following total hip replacement.Haemostasis, 2000,30 Suppl 2:130 - 135.

28 Matzsch T. Thromboprophylaxis with low-molecular-weight heparin: economic considerations. Haemostasis, 2000,30 suppl 2:141-145.

29 Gordois A, Posnett J, Borris L, et al. The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery. J Thromb Haemost, 2003, 1: 2167 - 2174.

30 王乐民，魏林. 肺栓塞与深静脉血栓形成. 第1版. 北京：人民卫生出版社，2001.11.

31 吕厚山, 徐斌. 人工关节置换术后下肢深静脉血栓形成, 中华骨科杂志, 1999, 19: 155-160.

(中华骨科杂志，2005，25：636 - 640)

 

 

本新闻共7页,当前在第7页  1  2  3  4  5  6  7